<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691533</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-ACLF-006</org_study_id>
    <nct_id>NCT02691533</nct_id>
  </id_info>
  <brief_title>To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure</brief_title>
  <official_title>To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study population: Patients admitted or seen in OPD (Out Patient Department), Department of
      Hepatology.

      Study design- Prospective Randomized Controlled Trial. Study period-January 2016 to May 2017
      Intervention- Subjects will be randomized into 3 groups Group A subjects will receive ω3 PUFA
      (Polyunsaturated Fatty Acids) (10% Omegavan 100 ml).

      Group B- will receive ω6 PUFA (Polyunsaturated Fatty Acids) (10% Intralipid 100 ml).

      Group C -Placebo group

      Monitoring and assessment- :- The following tests will be done in these patients:-

        1. Complete clinical examination.

        2. Serum electrolytes- sodium, potassium, calcium, magnesium, phosphate levels

        3. BUN (Blood Urea Nitrogen)

        4. Serum free fatty acid levels

        5. Lipid profile.

        6. Arterial ammonia

        7. Arterial lactate

        8. Blood sugar and serum insulin levels
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of intravenous lipid emulsions (w3/ w6) on systemic inflammation and endotoxemia levels at the end of 5 days.</measure>
    <time_frame>5 days</time_frame>
    <description>Decrease in endotoxins levels , TNF alpha,ilnterleukin 6,ilnterleukin 10,Monocyte/ macrophage activation etc.
All of them are markers of inflammation. The outcome systemic inflammation is a composite outcome which includes all the above mentioned markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of sepsis and related complications</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of lipid infusion (w3/w6) on metabolic parameters viz., serum triglyceride levels, serum ketone levels, free fatty acid levels and arterial lactate levels.</measure>
    <time_frame>5 days</time_frame>
    <description>Metabolic parameter is a composite outcome of all the above said markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of lipid infusion (w3/w6) on nitrogen balance.</measure>
    <time_frame>5 days</time_frame>
    <description>Improvement or deterioration in urinary urea nitrogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of lipid infusion (w3/w6) on International Normalized Ratio (INR).</measure>
    <time_frame>5 days</time_frame>
    <description>Effect is defined as INR (International Normalized Ratio) value within normal limit or improvement as compare to baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress response to lipid infusion</measure>
    <time_frame>5 days</time_frame>
    <description>Oxidative stress response is based on the Improvement or deterioration in Isoprostane levels in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of lipid infusion(w3/w6) on 28day mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>ω3 PUFA(10% Omegavan 100 ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ω6 PUFA (20% Intralipid 50 ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Lipid Emulsion will be given in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)</intervention_name>
    <arm_group_label>ω3 PUFA(10% Omegavan 100 ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)</intervention_name>
    <arm_group_label>ω6 PUFA (20% Intralipid 50 ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No Lipid Emulsion/Placebo</intervention_name>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute on Chronic Liver Failure (ACLF) patients aged 18 years and above

          -  Patients tolerating enteral nutrition

          -  Patients with no overt sepsis - no fever, sterile blood and urine cultures,
             procalcitonin &lt;2

        Exclusion Criteria:

          -  Active ongoing GI bleed

          -  Allergy to soya oil, eggs, peanuts or other ingredients of intralipid.

          -  Co-morbidities like Diabetes mellitus, hyperlipidemia, CAD and hypothyroidism.

          -  Renal failure (S.creatinine &gt; 2.5mg%)

          -  Pregnancy

          -  Patients with shock requiring vasopressor support

          -  Patients on anticoagulants

          -  Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Anand Kulkarni V, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2016</study_first_submitted>
  <study_first_submitted_qc>February 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
    <mesh_term>Fat Emulsions, Intravenous</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

